Venus Remedies receives EU patent for 'Sulbactomax'

Venus Remedies has received European Union patent for its researched anti-infection product 'Sulbactomax'. According to a company announcement, the patent granted by European Patent Organisation (EPO) covers the entire EU region.

Sulbactomax is capable of replacing a larger share of ceftriaxone market, which is a preferred antibiotic till now, said the company in a stock exchange announcement. This is also India's first

researched anti-infection product for catering bacterial resistance to get EU patent, it added.

The company plans to enter the EU market through CTD (common technical document) route and will be able to launch the product by 2013. The patent is valid until November 2025. The company

 

is also considering tie-ups with multinational companies for out licencing the product in geographies where it holds the patent for Sulbactomax.